Pharmacokinetic profile and in vivo anticancer efficacy of anagrelide administered subcutaneously in rodents
Sign Up to like & getrecommendations! Published in 2025 at "Drug Delivery"
DOI: 10.1080/10717544.2025.2463433
Abstract: Abstract Anagrelide (ANA) is a phosphodiesterase 3A (PDE3A) inhibitor, commonly prescribed for essential thrombocythemia. It also functions as a molecular glue, inducing complex formation between PDE3A and Schlafen 12. This association either triggers apoptosis or… read more here.
Keywords: profile vivo; vivo anticancer; efficacy; tumor ... See more keywords